• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results

    3/2/26 9:02:00 AM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email

    New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risks

    SECAUCUS, N.J., March 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced Quest AI Companion, a new AI-powered chat feature that helps individuals analyze, understand and act on their Quest laboratory test results with their healthcare provider. 

    questhealth.com logo (PRNewsfoto/Quest Diagnostics)

    Available now to all adult users of the company's secure, free patient mobile app and portal MyQuest, individuals can engage Quest AI Companion with questions about their test results and immediately receive personalized, easy-to-understand explanations, without leaving the integrated, HIPAA-compliant, MyQuest solution.

    "Patients often tell us they want help simplifying and understanding their test results and what the results communicate about their health," said Nicole Antonson, vice president of digital solutions and interoperability, Quest Diagnostics. "For more than 50 years, Quest has been a trusted provider of laboratory results. Now, Quest AI Companion builds on this history and empowers patients to analyze their results and spot trends they can discuss with their healthcare provider, for smarter and simpler testing that illuminates a path to better health."

    The new tool is unique because it seamlessly accesses and analyzes up to five years of an individual's lab data from Quest results reports to identify trends and patterns that may indicate health risks. As the Quest AI Companion operates within the secure MyQuest platform, individuals do not need to manually input their laboratory results into a public AI tool, avoiding concerns that may arise when sharing private health data with publicly accessible AI technologies. In addition, users can prompt the tool to define test names and medical terminology from their results reports, as well as translate the meaning of lab values, such as high, low, or within a reference range. Users can also prompt the AI Companion to assist with composing questions they can ask their healthcare provider, empowering patients to have more informed conversations with clinicians.

    While the use of AI technologies is growing across the healthcare industry, recent reports suggest most individuals do not access Gen AI apps to analyze their personal health data. In a survey conducted by Quest about the use of AI, participants cited privacy and data security, alongside accuracy and reliability, as concerns about the use of AI.

    "People want to understand their lab data, but not everyone feels comfortable uploading their health data to public AI platforms. Quest AI Companion empowers people to access the benefits of gen AI from a healthcare services provider they already know and trust to manage their most personal lab information," said Yuri Fesko, M.D., senior vice president and chief medical officer, Quest Diagnostics.

    Powered by Google's Gemini family of models, Quest AI Companion is the result of a strategic collaboration with Google Cloud, established in March 2025. Through this relationship, Quest integrates Google Cloud's advanced AI technologies to streamline data management and improve customer experiences. The parties plan to continue to work together to aid patients and providers through innovation.

    Individuals interested in Quest AI Companion can now access the service through their MyQuest account. Through MyQuest, patients can also schedule appointments, access test results and pay bills. For more information, visit MyQuest.QuestDiagnostics.com.

    Quest AI Companion is a chat feature intended for individuals to analyze and understand their Quest laboratory test results with their healthcare provider. Users must be at least age 18. Quest AI Companion is not a substitute for professional medical advice or visits to a healthcare provider. Patients should continue to consult with a healthcare provider about test results and any symptoms they may be experiencing. The Quest AI Companion is for educational purposes only and not for use in the diagnosis of disease or other conditions. The information provided by this system should not be used to start, stop, or change any course of treatment unless advised by your healthcare provider.

    About Quest Diagnostics

    Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-introduces-ai-companion-to-help-patients-understand-and-act-on-lab-test-results-302700483.html

    SOURCE Quest Diagnostics

    Get the next $DGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    1/30/2026$210.00Equal Weight → Overweight
    Barclays
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP for Diagnostic Services Plewman Patrick covered exercise/tax liability with 537 shares, sold $196,227 worth of shares (958 units at $204.83) and was granted 1,952 shares, increasing direct ownership by 3% to 15,838 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    2/20/26 5:13:11 PM ET
    $DGX
    Medical Specialities
    Health Care

    Executive Vice President & CFO Samad Sam was granted 4,034 shares and covered exercise/tax liability with 1,865 shares, increasing direct ownership by 8% to 27,910 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    2/20/26 5:12:39 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP & General Counsel Prevoznik Michael E sold $227,566 worth of shares (1,111 units at $204.83), was granted 2,013 shares and covered exercise/tax liability with 648 shares, increasing direct ownership by 0.67% to 38,371 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    2/20/26 5:12:09 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics upgraded by Barclays with a new price target

    Barclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00

    1/30/26 6:40:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results

    New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risksSECAUCUS, N.J., March 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced Quest AI Companion, a new AI-powered chat feature that helps individuals analyze, understand and act on their Quest laboratory test results with their healthcare provider.  Available now to all adult users of the company's secure, free patient mobile app and portal MyQuest, individuals can enga

    3/2/26 9:02:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer

    Veteran M&A and transformation leader from Danaher and Patheon joins the Quest Diagnostics executive teamSECAUCUS, N.J., Feb. 26, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced that Benjamin Beauvalot, a highly accomplished leader with more than two decades of experience in business strategy and transformation, including mergers and acquisitions (M&A), has joined the company as senior vice president, chief strategy and M&A officer. In this role, Mr. Beauvalot is responsible for developing the company's gr

    2/26/26 8:24:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference

    SECAUCUS, N.J., Feb. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Leerink 2026 Global Healthcare Conference in Miami on Wednesday, March 11, 2026, at 8:00 a.m. Eastern Time. The Fireside Chat and Q&A session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagn

    2/25/26 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    SEC Filings

    View All

    SEC Form 10-K filed by Quest Diagnostics Incorporated

    10-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    2/26/26 4:38:46 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    2/10/26 6:53:25 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    1/12/26 4:37:53 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

    Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024   Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno

    2/10/26 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

    SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's

    2/10/26 6:33:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026

    SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast

    1/8/26 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    View All

    Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

    Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke

    1/15/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/7/23 1:25:52 PM ET
    $DGX
    Medical Specialities
    Health Care